Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)

Eitemau Tebyg

• ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
  gan: Orentas, Rimas J, et al.
  Cyhoeddwyd: (2013)
• Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
  gan: Tschernia, Nicholas, et al.
  Cyhoeddwyd: (2014)
• Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
  gan: Walker, Alec J., et al.
  Cyhoeddwyd: (2017)
• Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors
  gan: Highfill, Steven L, et al.
  Cyhoeddwyd: (2013)
• Immunotherapy Targets in Pediatric Cancer
  gan: Orentas, Rimas J., et al.
  Cyhoeddwyd: (2012)